Drugs & 
Pill 
Drug Interaction 
Symptom 
Side 
Conditions 
Treatment 
Compare 
My Med 
Discount 
FDA 
Price 
Phonetic 
Health Drugs.com is the most popular, comprehensive and up-to-date source of drug information online. Providing free, peer-reviewed, accurate and independent data on more than 24,000 prescription drugs, over-the-counter medicines & natural products.
FDA Approves Tryptyr (acoltremon) Ophthalmic Solution for the Treatment of Dry Eye Disease
(BUSINESS WIRE) May 28, 2025 -- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S....
US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon Hadlima (adalimumab-bwwd) Injection
(BUSINESS WIRE) May 27, 2025 -- Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced that the US Food and Drug Administration (FDA)...
FDA Approves Starjemza (ustekinumab-hmny), a Biosimilar to Stelara
Guangzhou and London – May 27, 2025 – Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing...
FDA Approves Yutrepia (treprostinil) Inhalation Powder for Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced...
FDA Approves Brekiya (dihydroergotamine mesylate) Injection for the Acute Treatment of Migraine and Cluster Headaches in Adults
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration...
Feeling Work Stress? Your Dog Might Be Feeling It Too
SATURDAY, May 31, 2025 — Stress from work doesn’t always stay at the office — and it may be affecting more than just your mood. A new study...
Monthly News Roundup - May 2025
AbbVie’s Emrelis Approved for Non-Small Cell Lung Cancer With High c-Met Protein Overexpression Emrelis (telisotuzumab vedotin) is a first-in-class,...
Colorado Reporting New Outbreak of Measles
As of today, the total measles case count in the United States is 1,088, according to the U.S. Centers for Disease Control and Prevention. Texas, which...
Physical Activity Linked to Better Survival for Specific Cancer Types
Engaging in leisure-time moderate- to vigorous-intensity physical activity (MVPA) is associated with better overall survival for participants with a history...
Dr. Robert Jarvik, Inventor of First Human Artificial Heart, Dies at 79
FRIDAY, May 30, 2025 — Dr. Robert Jarvik, the man behind the world’s first permanent artificial heart used in a human, has died. He...
18.6 Million Cancer Survivors in the United States as of Jan. 1, 2025
The number of cancer survivors in the United States reached 18.6 million as of Jan. 1, 2025, and is projected to exceed 22 million by 2035, according to...
FDA Chief: COVID Vaccine in Pregnancy Should Be Personal Choice
FRIDAY, May 30, 2025 — Federal health officials have pulled back a key recommendation that pregnant women get the COVID-19 vaccine — causing...
16 Updates, Four New Recommendations Issued for Management of Pediatric VTE
In clinical guidelines issued by the American Society of Hematology and the International Society on Thrombosis and Haemostasis, and published online May...
Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials
TARRYTOWN, N.Y. and PARIS, May 30, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today...
NIH Scientists Pioneer Promising Treatment for Intractable Cancer Pain
National Institute of Health (NIH) scientists report that a first-in-human clinical trial of a new therapy based on the plant-derived molecule resiniferatoxin...
Stealth BioTherapeutics Announces “Path Forward” Despite Disappointing Delay for Ultra-Rare Barth Syndrome
NEEDHAM, Mass., May 29, 2025 /PRNewswire/ — Stealth BioTherapeutics Inc. (the “Company” or “Stealth”), a clinical-stage...
Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFRMutated Non-Small Cell Lung Cancer Voluntarily Withdrawn
Tokyo and Basking Ridge, NJ – May 29, 2025 – The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo...
Vitamin D Might Fend Off Biological Aging
TUESDAY, May 27, 2025 — Vitamin D supplements might be a veritable Fountain of Youth, capable of slowing down a person’s biological aging,...
Otsuka Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
PRINCETON, N.J. and TOKYO, JAPAN May 27, 2025 – Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical...
Recently Added
Recently added consumer and prescribing information: Miudella, Opdivo Qvantig, Alyftrek, Crenessity, Ensacove, Steqeyma, Yesintek, Revuforj, Danziten, Aucatzyl
For Consumers
- Cerner Multum Drug Information
- Micromedex Advanced Consumer
- Natural Product Information for the Consumer
For Professionals
- FDA Professional Information
- Professional Patient Advice
- ASHP Monographs (AHFS DI)
- Micromedex CareNotes
- Natural Product Information
For Researchers
Latest FDA New Drug Approvals
- Tryptyr Tryptyr (acoltremon) is a first-in-class TRPM8 thermoreceptor agonist indicated for the treatment of the signs and symptoms of dry eye disease.
- Starjemza Starjemza (ustekinumab-hmny) is a human interleukin-12 and -23 antagonist biosimilar to Stelara used for the treatment of plaque psoriasis...
- Yutrepia Yutrepia (treprostinil) is an inhaled dry powder formulation of the prostacyclin mimetic treprostinil approved for the treatment of...
Drug Information
Tools
- Interaction Checker
- Pill Identifier
- Symptom Checker
- Medication Record
- Mobile Apps
- Drug Imprint Codes
- Community Support
- Compare Drugs
News & Alerts
- Medical News
- Clinical Trial Results
- FDA Drug Alerts
- FDA Consumer Updates
- New FDA Approvals
- New Drug Applications
- Drug Shortages
- Video Center
- Popular Articles
Professionals
Top 100 Drugs
- Abilify
- Adderall
- Aimovig
- Ambien
- Atorvastatin
- Austedo
- Avastin
- Benlysta
- Biktarvy
- Botox
- Breztri
- Buprenorphine
- Cabenuva
- Cimzia
- Cosentyx
- Diazepam
- Descovy
- Diclofenac
- Doxycycline
- Duloxetine
- Dupixent
- Emgality
- Enhertu
- Entyvio
- Epclusa
- Erleada
- Evenity
- Fasenra
- Farxiga
- Gabapentin
- Gemtesa
- Humira
- Ibuprofen
- Imbruvica
- Januvia
- Jardiance
- Kesimpta
- Keytruda
- Kisqali
- Leqembi
- Leqvio
- Lexapro
- Lybalvi
- Lyrica
- Metformin
- Methadone
- Methotrexate
- Mounjaro
- Naloxone
- Naltrexone
- Nucala
- Nurtec
- Ofev
- Opdivo
- Orladeyo
- Otezla
- Oxycodone
- Ozempic
- Paxlovid
- Penicillin
- Praluent
- Prednisone
- Prozac
- Qulipta
- Quviviq
- Reblozyl
- Repatha
- Restasis
- Rexulti
- Rybelsus
- Semaglutide
- Seroquel
- Sildenafil
- Skyrizi
- Sotyktu
- Stelara
- Sublocade
- Taltz
- Tepezza
- Tramadol
- Tremfya
- Trintellix
- Tylenol
- Ubrelvy
- Vabysmo
- Venclexta
- Verzenio
- Viagra
- Vijoice
- Vraylar
- Vumerity
- Vyepti
- Vyvanse
- Vyvgart
- Wegovy
- Wellbutrin
- Xanax
- Xolair
- Xyrem
- Zepbound
